Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.

Literature DB >> 27090640

Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.

Ion Cristóbal¹, Federico Rojo², Juan Madoz-Gúrpide², Jesús García-Foncillas¹.

Abstract

Aberrant activation of the Wnt/β-catenin pathway and polo-like kinase 1 (Plk1) overexpression represent two common events in prostate cancer with relevant functional implications. This minireview analyzes their potential therapeutic significance in prostate cancer based on their role as androgen receptor (AR) signaling regulators and the pivotal role of the tumor suppressor protein phosphatase 2A (PP2A) modulating these pathways.

Entities: Disease Gene

Mesh：

Substances：

Year: 2016 PMID： 27090640 PMCID： PMC4907099 DOI： 10.1128/MCB.00130-16

Source DB: PubMed Journal: Mol Cell Biol ISSN： 0270-7306 Impact factor: 4.272

108 in total

1. Overexpression of Plk1 promotes malignant progress in human esophageal squamous cell carcinoma.

Authors: Chunling Zhao; Lei Gong; Wentong Li; Limei Chen
Journal: J Cancer Res Clin Oncol Date: 2010-01 Impact factor: 4.553

2. Polo-like kinase 1-mediated phosphorylation of the GTP-binding protein Ran is important for bipolar spindle formation.

Authors: Yang Feng; Jin Hui Yuan; Sharon C Maloid; Rebecca Fisher; Terry D Copeland; Dan L Longo; Thomas P Conrads; Timothy D Veenstra; Andrea Ferris; Steve Hughes; Dimiter S Dimitrov; Douglass K Ferris
Journal: Biochem Biophys Res Commun Date: 2006-08-14 Impact factor: 3.575

3. Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery.

Authors: X Shawn Liu; Hongchang Li; Bing Song; Xiaoqi Liu
Journal: EMBO Rep Date: 2010-06-25 Impact factor: 8.807

4. Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells.

Authors: Xue-Hua Chen; Bin Lan; Ying Qu; Xiao-Qing Zhang; Qu Cai; Bing-Ya Liu; Zheng-Gang Zhu
Journal: World J Gastroenterol Date: 2006-01-07 Impact factor: 5.742

5. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.

Authors: Minakshi Nihal; Nathalie Stutz; Travis Schmit; Nihal Ahmad; Gary S Wood
Journal: Cell Cycle Date: 2011-04-15 Impact factor: 4.534

6. Expression of PLK1 and survivin in non-Hodgkin's lymphoma treated with CHOP.

Authors: Lin Liu; Min Zhang; Ping Zou
Journal: Acta Pharmacol Sin Date: 2008-03 Impact factor: 6.150

7. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.

Authors: Gaoping Chen; Nicholas Shukeir; Anil Potti; Kanishka Sircar; Armen Aprikian; David Goltzman; Shafaat A Rabbani
Journal: Cancer Date: 2004-09-15 Impact factor: 6.860

8. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease.

Authors: Lucas Kneisel; Klaus Strebhardt; August Bernd; Manfred Wolter; Angelika Binder; Roland Kaufmann
Journal: J Cutan Pathol Date: 2002-07 Impact factor: 1.587

9. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.

Authors: Youquan Bu; Zhengmei Yang; Quanhai Li; Fangzhou Song
Journal: Oncology Date: 2008-08-20 Impact factor: 2.935

Review 10. Targeting the adaptive molecular landscape of castration-resistant prostate cancer.

Authors: Alexander W Wyatt; Martin E Gleave
Journal: EMBO Mol Med Date: 2015-07 Impact factor: 12.137

8 in total

1. Epigenetic analysis identifies factors driving racial disparity in prostate cancer.

Authors: Richa Rai; Shalini S Yadav; Heng Pan; Irtaza Khan; James O'Connor; Mohammed Alshalalfa; Elai Davicioni; Emanuela Taioli; Olivier Elemento; Ashutosh K Tewari; Kamlesh K Yadav
Journal: Cancer Rep (Hoboken) Date: 2018-12-13

2. Frequently rearranged and overexpressed δ-catenin is responsible for low sensitivity of prostate cancer cells to androgen receptor and β-catenin antagonists.

Authors: Piyan Zhang; Janet Schaefer-Klein; John C Cheville; George Vasmatzis; Irina V Kovtun
Journal: Oncotarget Date: 2018-05-11

3. PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.

Authors: Laura L Stafman; Adele P Williams; Raoud Marayati; Jamie M Aye; Jerry E Stewart; Elizabeth Mroczek-Musulman; Elizabeth A Beierle
Journal: PLoS One Date: 2019-04-10 Impact factor: 3.240

8. Aberrant expression of vasculogenic mimicry, PRRX1, and CIP2A in clear cell renal cell carcinoma and its clinicopathological significance.

Authors: Xiaolin Wang; Ruixue Yang; Qi Wang; Yichao Wang; Hongfei Ci; Shiwu Wu
Journal: Medicine (Baltimore) Date: 2019-09 Impact factor: 1.817